Mostrar el registro sencillo del ítem
Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports
dc.creator | Kyriakoulis K.G., Kollias A., Kyriakoulis I.G., Kyprianou I.A., Papachrysostomou C., Makaronis P., Kotronias R.A., Terentes-Printzios D., Toskas I., Mikhailidis D.P. | en |
dc.date.accessioned | 2023-01-31T08:47:45Z | |
dc.date.available | 2023-01-31T08:47:45Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.2174/1570161119666210824160332 | |
dc.identifier.issn | 15701611 | |
dc.identifier.uri | http://hdl.handle.net/11615/75578 | |
dc.description.abstract | Background: Venous Thromboembolism (VTE) is common among patients with severe Coronavirus Disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients has been associated with survival benefit; however, the optimal thromboprophylaxis strategy has not yet been defined. Objective: To identify published guidance reports by national and international societies regarding thromboprophylaxis strategies in COVID-19 patients in different settings (outpatients, hospitalized, post-discharge). Methods: A systematic review of the literature (Pubmed/EMBASE) was conducted independently by two investigators. Results: Among 1942 initially identified articles, 33 guidance documents were included: 20 published by national and 13 by international societies. These documents provide recommendations mainly for hospitalized (97% of reports) and post-discharge (75%) COVID-19 patients, and less so for outpatients (34%). Thrombotic and bleeding risk stratification prior to any treatment decision is the cornerstone of all suggested thromboprophylaxis strategies; 81% of the documents recommend thromboprophylaxis for all hospitalized patients with a prophylactic dosage of low molecular weight heparin irrespective of VTE risk. Intermediate or therapeutic dose intensity is recommended in high VTE risk patients by 56% and 28% of documents, respectively. Mechanical thromboprophylaxis is suggested in case of high bleeding risk or contraindication to pharmacological thromboprophylaxis (59% of documents). Extended pharmacological thromboprophylaxis is recommended for patients with high VTE risk after hospital discharge (63% of documents). For non-hospitalized outpatients, 28% of documents recommend pharmacological thromboprophylaxis for high VTE risk. Conclusion: The current guidance identifies thromboprophylaxis in COVID-19 patients, especially during hospitalization, as of major importance for the prevention of VTE. Recommendations are derived from limited evidence from observational studies. © 2022 Bentham Science Publishers. | en |
dc.language.iso | en | en |
dc.source | Current Vascular Pharmacology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123646960&doi=10.2174%2f1570161119666210824160332&partnerID=40&md5=0b02073219ab45d18925906947379cf6 | |
dc.subject | adult respiratory distress syndrome | en |
dc.subject | anticoagulant therapy | en |
dc.subject | artificial ventilation | en |
dc.subject | asthma | en |
dc.subject | atrial fibrillation | en |
dc.subject | bleeding | en |
dc.subject | cardiovascular mortality | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | creatinine clearance | en |
dc.subject | deep vein thrombosis | en |
dc.subject | dyspnea | en |
dc.subject | extracorporeal oxygenation | en |
dc.subject | genetic polymorphism | en |
dc.subject | hospital discharge | en |
dc.subject | hospital mortality | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | intensive care unit | en |
dc.subject | lung embolism | en |
dc.subject | obesity | en |
dc.subject | platelet count | en |
dc.subject | Review | en |
dc.subject | risk assessment | en |
dc.subject | systematic review | en |
dc.subject | thrombocyte activation | en |
dc.subject | thrombocytopenia | en |
dc.subject | thrombosis prevention | en |
dc.subject | venous thromboembolism | en |
dc.subject | aftercare | en |
dc.subject | risk factor | en |
dc.subject | venous thromboembolism | en |
dc.subject | anticoagulant agent | en |
dc.subject | Aftercare | en |
dc.subject | Anticoagulants | en |
dc.subject | COVID-19 | en |
dc.subject | Humans | en |
dc.subject | Patient Discharge | en |
dc.subject | Risk Factors | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Venous Thromboembolism | en |
dc.subject | Bentham Science Publishers | en |
dc.title | Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports | en |
dc.type | other | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |